Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Xenon ( (XENE) ) is now available.
Xenon Pharmaceuticals used the 2026 J.P. Morgan Healthcare Conference to highlight approaching clinical and regulatory milestones for its lead candidate azetukalner and to showcase progress across a broader neurology and pain pipeline. The company expects topline Phase 3 X-TOLE2 data for azetukalner in focal onset seizures in March 2026, with a planned U.S. regulatory filing in the second half of 2026, and is running five additional Phase 3 trials across epilepsy and mood disorders, including global epilepsy studies aimed at ex-U.S. submissions and major depressive and bipolar depression programs, supported by long-term data showing sustained seizure reduction and seizure freedom in a subset of patients. Xenon is also advancing its early-stage pain portfolio, with Phase 1 data for its NaV1.7 inhibitor XEN1701 and KV7 modulator XEN1120 expected in 2026 to underpin Phase 2 proof-of-concept studies in pain, signaling a bid to broaden its commercial opportunity beyond epilepsy and depression and strengthen its position as a key player in CNS therapeutics.
The most recent analyst rating on (XENE) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.
Spark’s Take on XENE Stock
According to Spark, TipRanks’ AI Analyst, XENE is a Neutral.
The score is driven primarily by weak financial performance (large losses and heavy cash burn), partially offset by an optimistic earnings-call outlook and runway guidance into 2027, plus supportive technical uptrend. Valuation remains constrained by negative earnings and lack of dividend support.
To see Spark’s full report on XENE stock, click here.
More about Xenon
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company specializing in the discovery, clinical development and commercialization of therapeutics targeting neurological and neuropsychiatric disorders. The company’s lead programs center on azetukalner for epilepsy and depression, alongside an emerging early-stage pain portfolio targeting ion channels such as NaV1.7 and KV7, positioning Xenon in high-need segments of the central nervous system market.
Average Trading Volume: 827,516
Technical Sentiment Signal: Buy
Current Market Cap: $3.19B
For a thorough assessment of XENE stock, go to TipRanks’ Stock Analysis page.